Journal September 26, 2026 5 min read

How AMPK activation changes with age

AMPK is a heterotrimeric serine/threonine kinase that senses cellular energy status. This page examines how AMPK activation changes with age, drawing on animal and in vitro studies, and highlights where evidence is limit

peptides-pro Editorial

AMPK and age-related changes in activation

AMP-activated protein kinase (AMPK) is a heterotrimeric serine/threonine protein kinase consisting of a catalytic α-subunit and regulatory β- and γ-subunits [8]. It functions as a cellular energy sensor and regulates multiple processes, including endothelial homeostasis [8]. In the context of aging, AMPK activation has been studied in various models, but direct evidence for how activation changes with age in humans is limited. Most findings come from animal or in vitro studies, and the specific mechanisms may not translate to human physiology.

The work centres on the AMPK signalling pathway, which is activated by increases in the AMP/ATP ratio and is involved in metabolic regulation, inflammation, and cellular stress responses [4].

Research Studies

Hepassocin and age-related liver senescence in mice

Hepassocin (HPS), a hepatokine, has been reported to prevent age-related liver senescence and facilitate liver regeneration by activating AMPK [7]. This finding is from animal models and suggests that AMPK activation may decline with age in the liver, but the study did not directly measure age-related changes in AMPK activation. The evidence is limited to preclinical models.

Pan-AMPK activator MK-8722 in human endothelial cells

In human endothelial cells, the pan-AMPK activator MK-8722 outperformed the AMPK activators SC4 and A-769662 in activating AMPK [8]. This in vitro study indicates that pharmacological activation of AMPK is possible in human cells, but it does not address how endogenous AMPK activation changes with age. The findings are specific to endothelial cells and cannot be extrapolated to whole-body aging.

Palmitic acid and AMPK suppression in airway epithelial cells

Obesity-related palmitic acid exacerbated IL-13-induced mucus phenotype in 16HBE airway epithelial cells via AMPK suppression [9]. This in vitro study links metabolic stress to reduced AMPK activation, but it does not examine age as a variable. The relevance to age-related changes in AMPK activation is indirect.

Exercise preconditioning and AMPK-ACC signaling in mouse myocardium

In C57BL/6J mice, six weeks of treadmill exercise preconditioning activated AMPK-ACC signaling and attenuated myocardial ischemia/reperfusion-induced ferroptosis [10]. This animal study shows that exercise can activate AMPK in the heart, but it does not compare young versus old animals. Therefore, it does not provide direct evidence on how AMPK activation changes with age.

Bitter melon compounds and AMPK activation in myotonic dystrophy type 1 myotubes

In C2C12 myotubes, a screen of 26 bitter melon-derived compounds identified BMC-25 as a potent AMPK activator, and it ameliorated the myotonic dystrophy type 1 skeletal muscle phenotype in a sex-specific manner [5]. This in vitro and animal study highlights that AMPK activation can be modulated pharmacologically, but it does not address age-related changes in AMPK activation. The model is specific to myotonic dystrophy type 1.

Oxidative eustress and AMPK activation in skeletal muscle cells

In C2C12 myoblasts/myotubes, redox-modulating stimuli associated with oxidative eustress, including hydrogen peroxide, nitric oxide donors, and angiotensin II, induced AKT and AMPK phosphorylation, GLUT4 translocation, and glucose uptake [2]. This in vitro study demonstrates that AMPK can be activated by moderate oxidative stress, but it does not investigate age as a factor. The findings are limited to skeletal muscle cells.

Salsalate and AMPK activation in renal epithelial cells

In renal epithelial cells, targeted analysis of salicylate binding partners revealed major AMPK dependency, and salsalate, an AMPK activator, ameliorated disease progression in a model of autosomal dominant polycystic kidney disease [3]. This study provides insight into AMPK activation mechanisms in kidney cells, but it does not examine age-related changes. The evidence is from preclinical models.

Astaxanthin and autophagy in granulosa cells from women with PMOS

In a pilot randomised trial involving 50 women with polyendocrine metabolic ovarian syndrome (PMOS)-related anovulatory infertility, astaxanthin (12 mg/day) modulated autophagy-related signalling in granulosa cells [1]. While this study involves human participants, it focuses on a specific clinical population and does not assess AMPK activation or age-related changes. The findings are limited to this context.

AMPK and macrophage crosstalk in diabetes

A review of AMPK and macrophage crosstalk in diabetes describes how AMPK suppresses pro-inflammatory M1 responses by inhibiting NF-κB and JNK signaling, activating CREB/SIRT1 pathways, and promoting oxidative metabolism [4]. This review synthesises evidence from various models, but it does not specifically address how AMPK activation changes with age. The mechanisms are relevant to inflammation and insulin resistance, which are associated with aging, but direct age-related data are lacking.

If you are reading this for personal health reasons

The compounds and research materials discussed here are sold for laboratory research purposes only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.